Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.77 |
| ▸ | POLB | P06746 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22378334 | 0.93 | TP53 (0.66) | TP53POLBGAATDP1MAPT | |
| SCHEMBL14680333 | 0.64 | POLB (0.51) | TP53POLBTDP1MAPT | |
| SCHEMBL24705203 | 0.58 | MAPT (0.50) | TP53TDP1MAPT | |
| SCHEMBL2223578 | 0.57 | FYN (0.48) | POLBGAAMAPT | |
| SCHEMBL15947884 | 0.56 | PDE4B (0.50) | MAPT | |
| SCHEMBL2616114 | 0.55 | IDO1 (0.47) | TP53POLBMAPT | |
| SCHEMBL13273284 | 0.54 | PDE4B (0.50) | — | |
| SCHEMBL10589866 | 0.54 | IDO1 (0.57) | TP53GAA | |
| SCHEMBL16047359 | 0.54 | NR1I3 (0.46) | — | |
| SCHEMBL2222137 | 0.53 | PDE4B (0.56) | POLBGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689392-B2 | Anti-cancer compounds targeting ral GTPases and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-06-23 | — | — | US | disclosed |
| US-20160280715-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-20160280715-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-9353121-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-05-31 | — | — | US | disclosed |
| US-9353121-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-05-31 | — | — | US | disclosed |
| US-20140315894-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315894-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2013096820-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315894-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | ARFGAP1, ARHGDIB, IQGAP1 | TP53 492/4885POLB 3140/4885GAA 1980/4885 |
| US-20160280715-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | ARFGAP1, ARHGDIB, IQGAP1 | TP53 492/4885POLB 3140/4885GAA 1980/4885 |
| US-10689392-B2 | Anti-cancer compounds targeting ral GTPases and methods of using the same | ARFGAP1, ARHGDIB, IQGAP1 | TP53 492/4885POLB 3140/4885GAA 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.